ATRT-02. THE AURORA KINASE A (AURKA) INHIBITOR ALISERTIB ACTS SYNERGISTICALLY WITH A POLO-LIKE KINASE 4 (PLK4) INHIBITOR TO TARGET ATYPICAL TERATOID / RHABDOID TUMOR (AT/RT) CELLS
نویسندگان
چکیده
منابع مشابه
Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor
Atypical teratoid rhabdoid tumor (ATRT) is an aggressive and malignant pediatric brain tumor. Polo-like kinase 1 (PLK1) is highly expressed in many cancers and essential for mitosis. Overexpression of PLK1 promotes chromosome instability and aneuploidy by overriding the G2-M DNA damage and spindle checkpoints. Recent studies suggest that targeting PLK1 by small molecule inhibitors is a promisin...
متن کاملAlisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children.
BACKGROUND Aurora Kinase A (AURKA) encodes a protein that regulates the formation and stability of the mitotic spindle and is highly active in atypical teratoid rhabdoid tumors (ATRT) through loss of the INI1 tumor suppressor gene. Alisertib (MLN8237) inhibits AURKA in vitro and in vivo. Given the strong preclinical data supporting the use of alisertib for ATRT patients, we sought and obtained ...
متن کاملAtypical Teratoid Rhabdoid Tumor (atrt) At-01. Pitfalls in the Diagnosis of Atypical Teratoid/rhabdoid Tumors (at/rt): Experiences from the European Rhabdoid Tumor Registry (eurhab) and the International Choroid Plexus Tumor Registry Cpt-siop
ATYPICAL TERATOID RHABDOID TUMOR
متن کاملSmall molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells.
Neuroblastoma (NB) is an often fatal pediatric tumor of neural crest origin. We previously isolated NB tumor-initiating cells (NB TIC) from bone marrow metastases that resemble cancer stem cells and form metastatic NB in immunodeficient animals with as few as ten cells. To identify signaling pathways important for the survival and self-renewal of NB TICs and potential therapeutic targets, we sc...
متن کاملThe polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells
Background Despite the availability of hundreds of cancer drugs, there is insufficient data on the efficacy of these drugs on the extremely heterogeneous tumor cell populations of glioblastoma (GBM). Results The PKIS of 357 compounds was initially evaluated in 15 different GSC lines which then led to a more focused screening of the 21 most highly active compounds in 11 unique GSC lines using ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-Oncology
سال: 2018
ISSN: 1522-8517,1523-5866
DOI: 10.1093/neuonc/noy059.001